Klaria announces positive results in a pre-clinical, proof-of-concept study with transmucosal oral film of Ketamine and files patent to protect the innovative formulation
Today, Klaria announces positive results in a pre-clinical Proof-of-Concept (PoC) study conducted with Ketamine formulated in the company’s proprietary alginate transmucosal film. With this data, the program is now ready for clinical development. Klaria’s development program will focus on the treatment of acute pain. The company also notes that this formulation of ketamine opens up the possibility of offering treatment-resistant depression patients a more attractive option to the currently marketed nasal spray. Furthermore, Klaria announces that it has filed for patent protection of the